News and Trends 8 Nov 2022 Does covid vaccination boost cancer treatment? Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. It was feared that vaccination against Covid-19 could reduce the success of cancer treatment or cause severe side effects. However, a recent study by the universities of Bonn, Germany, and Shanxi, China, say this isn’t the case. According […] November 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2022 Google and Meta AI could boost cancer research and drug discovery Encoded in the DNA, a protein may be represented as a thread of hundreds of individual molecules called amino acids, linked together. Depending on the particular amino acids combination, a protein folds in a particular way, resulting in a functional 3D shape. The shape makes the function, and with 20 different amino acids available, the […] November 8, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 8 Nov 2022 JelloX Biotech helps doctors diagnose and treat cancer tumors with speed and accuracy Taiwan-based start-up, JelloX Biotech, says its products will help doctors diagnose and treat cancer tumors with speed and accuracy without an added strain on budgets. The company made its debut at Intel Innovation in September. JelloX has gained the attention of healthcare experts and pharmaceutical brands for its potential for the future of cancer pathology using […] November 8, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2022 Vir Biotech presents new data for functional cure of chronic Hep B virus Vir Biotechnology, Inc. today (November 8) announced new data from its robust hepatitis B virus (HBV) portfolio aimed at achieving a functional cure. These data, plus health outcomes research, are being presented at the American Association for the Study of Liver Diseases (AASLD). The Liver Meeting was delivered in two oral presentations, both of which were selected […] November 8, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 8 Nov 2022 ISA Pharmaceuticals’ Amplivant adjuvant boosts immune response in SLP immunotherapy ISA Pharmaceuticals B.V, a Netherlands-based clinical stage biotech developing immunotherapies to treat cancers and infectious diseases has had a phase 1 clinical study published. The study, using ISA Pharmaceuticals’ Amplivant adjuvant and synthetic long peptide (SLP) therapeutic vaccine technology was published by Leiden University Medical Centre (LUMC) in the Journal for ImmunoTherapy for Cancer. It […] November 8, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2022 MedinCell’s partner AIC registers trial for drug for total knee replacement pain A partner of MedinCell, Arthritis Innovation Corporation (AIC), has registered a phase 3 trial to look into an alternative drug to deal with pain after total knee replacement (TKR). Arthritis Innovation Corporation conducts and finances all development activities of the drug F14, or mdc-CWM, being trialed. It was registered with the safety and efficacy study […] November 8, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2022 AI program yields multiple novel RSV drug targets Poolbeg Pharma says it has made a breakthrough in its Artificial Intelligence (AI) program with partner OneThree Biotech, Inc. through the discovery of novel drug targets for the treatment of respiratory syncytial virus (RSV). Following the completion of the build and optimization of a tailored AI model in June 2022, the OneThree team, using its […] November 8, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2022 Collaboration to develop CAR-T cell therapy for cutaneous T-cell lymphoma The Peter MacCallum Cancer Centre (Peter Mac) and Cartherics Pty Ltd (Cartherics) have entered into a collaborative development program agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-001) for the treatment of cutaneous T-cell lymphoma (CTCL). “Patients with advanced stages of cutaneous T-cell lymphomas often have few treatment options left when their disease […] November 8, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2022 Study shows enhanced drug delivery to the brain In a study recently published in the journal Nature Biomedical Engineering, Japanese researchers used a method called “lasso-grafting” to design therapeutics with enhanced longevity and brain penetration. Cell growth and repair are stimulated by biomolecules known as cytokines and growth factors. Unfortunately, delivering adequate concentrations of these molecules to the brain for treating neurological conditions […] November 8, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2022 BC Platforms receives $20M financing Healthcare data management and analytics company BC Platforms (BCP) has closed a CHF 20 million ($20 million) financing round. The growth equity financing was led by new investor Jolt Capital (HQ Paris), a fully independent private equity firm that specializes in growth capital deeptech in Europe. The new financing will help accelerate the expansion of […] November 8, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2022 Telix Pharmaceuticals sees positive results in kidney cancer imaging study Telix Pharmaceuticals Limited said it has highly positive top-line results from its pivotal phase III study of its investigational renal (kidney) cancer positron emission tomography (PET) imaging agent, TLX250-CDx (89 Zr- DFO-girentuximab). The ZIRCON study (Zirconium in Renal Cancer Oncology, NCT03849118) has met its co-primary and secondary endpoints. The study results delivered 86% sensitivity and […] November 8, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2022 Lipum starts chronic inflammatory disease drug study Lipum AB (publ) says its phase 1 clinical study with the drug candidate SOL-116 has started and is progressing according to plan. A first dose group of eight healthy volunteers have received a dose, with two volunteers receiving placebo. Lipum’s drug candidate SOL-116 is a fully humanized antibody that is intended to address a major […] November 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email